These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

482 related articles for article (PubMed ID: 35241833)

  • 1. A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance.
    Huang AC; Zappasodi R
    Nat Immunol; 2022 May; 23(5):660-670. PubMed ID: 35241833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of resistance to immune checkpoint inhibitors in melanoma: What we have to overcome?
    Ziogas DC; Theocharopoulos C; Koutouratsas T; Haanen J; Gogas H
    Cancer Treat Rev; 2023 Feb; 113():102499. PubMed ID: 36542945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy for Melanoma: The Significance of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma.
    Fujimura T; Muto Y; Asano Y
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic and transcriptional changes in IFNγ pathway genes are putative biomarkers of response to ipilimumab immunotherapy in melanoma patients.
    Hargadon KM; Győrffy B; McGee TJ
    Expert Rev Clin Immunol; 2020 Dec; 16(12):1099-1103. PubMed ID: 33151785
    [No Abstract]   [Full Text] [Related]  

  • 5. Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis.
    Alrabadi NN; Abushukair HM; Ababneh OE; Syaj SS; Al-Horani SS; Qarqash AA; Darabseh OA; Al-Sous MM; Al-Aomar SR; Ahmed YB; Haddad R; Al Qarqaz FA
    Clin Transl Oncol; 2021 Sep; 23(9):1885-1904. PubMed ID: 33877531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
    Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor microenvironment changes leading to resistance of immune checkpoint inhibitors in metastatic melanoma and strategies to overcome resistance.
    Pulluri B; Kumar A; Shaheen M; Jeter J; Sundararajan S
    Pharmacol Res; 2017 Sep; 123():95-102. PubMed ID: 28690075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double Trouble: Immunotherapy Doublets in Melanoma-Approved and Novel Combinations to Optimize Treatment in Advanced Melanoma.
    Dimitriou F; Hauschild A; Mehnert JM; Long GV
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-22. PubMed ID: 35658500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The foundations of immune checkpoint blockade and the ipilimumab approval decennial.
    Korman AJ; Garrett-Thomson SC; Lonberg N
    Nat Rev Drug Discov; 2022 Jul; 21(7):509-528. PubMed ID: 34937915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MIF inhibition as a strategy for overcoming resistance to immune checkpoint blockade therapy in melanoma.
    de Azevedo RA; Shoshan E; Whang S; Markel G; Jaiswal AR; Liu A; Curran MA; Travassos LR; Bar-Eli M
    Oncoimmunology; 2020 Dec; 9(1):1846915. PubMed ID: 33344042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Volume increase of spleen in melanoma patients undergoing immune checkpoint blockade.
    Susok L; Reinert D; Lukas C; Stockfleth E; Gambichler T
    Immunotherapy; 2021 Aug; 13(11):885-891. PubMed ID: 34229447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding the Tumor Microenvironment in Melanoma Patients with In-Transit Metastases and Its Impacts on Immune Checkpoint Immunotherapy Responses.
    Tian J; Quek C
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy.
    Tang T; Huang X; Zhang G; Hong Z; Bai X; Liang T
    Signal Transduct Target Ther; 2021 Feb; 6(1):72. PubMed ID: 33608497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Granulocyte Apheresis: Can It Be Associated with Anti PD-1 Therapy for Melanoma?
    Sernicola A; Colpo A; Leahu AI; Alaibac M
    Medicina (Kaunas); 2022 Oct; 58(10):. PubMed ID: 36295558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
    Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
    JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.
    Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment.
    Lisi L; Lacal PM; Martire M; Navarra P; Graziani G
    Pharmacol Res; 2022 Jan; 175():105997. PubMed ID: 34826600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
    La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB
    Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action.
    Willsmore ZN; Coumbe BGT; Crescioli S; Reci S; Gupta A; Harris RJ; Chenoweth A; Chauhan J; Bax HJ; McCraw A; Cheung A; Osborn G; Hoffmann RM; Nakamura M; Laddach R; Geh JLC; MacKenzie-Ross A; Healy C; Tsoka S; Spicer JF; Josephs DH; Papa S; Lacy KE; Karagiannis SN
    Eur J Immunol; 2021 Mar; 51(3):544-556. PubMed ID: 33450785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.